Bros. Advisors Lp Baker Buys 100,000 Shares of Incyte Corporation (INCY) Stock

Incyte Corporation (NASDAQ:INCY) Director Bros. Advisors Lp Baker acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The shares were acquired at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Incyte Corporation (NASDAQ:INCY) opened at 119.15 on Friday. The company’s 50-day moving average is $127.40 and its 200 day moving average is $130.21. The stock’s market capitalization is $24.51 billion. Incyte Corporation has a 1-year low of $81.49 and a 1-year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $326.40 million during the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. Incyte Corporation’s revenue was up 32.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 EPS. Equities analysts predict that Incyte Corporation will post ($0.84) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Bros. Advisors Lp Baker Buys 100,000 Shares of Incyte Corporation (INCY) Stock” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/09/17/bros-advisors-lp-baker-purchases-100000-shares-of-incyte-corporation-incy-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of INCY. Tower Research Capital LLC TRC purchased a new stake in shares of Incyte Corporation during the first quarter worth $105,000. D. Scott Neal Inc. purchased a new stake in shares of Incyte Corporation during the second quarter worth $103,000. Cornerstone Advisors Inc. grew its holdings in shares of Incyte Corporation by 19.6% during the second quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 145 shares in the last quarter. FNY Partners Fund LP grew its holdings in shares of Incyte Corporation by 4,825.0% during the first quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 965 shares in the last quarter. Finally, Exane Asset Management purchased a new stake in shares of Incyte Corporation during the second quarter worth $126,000. 91.06% of the stock is owned by institutional investors.

Several research analysts have recently issued reports on INCY shares. J P Morgan Chase & Co reiterated a “buy” rating and issued a $149.00 target price on shares of Incyte Corporation in a research note on Thursday, August 31st. Zacks Investment Research upgraded shares of Incyte Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. BMO Capital Markets restated an “outperform” rating and set a $172.00 price objective on shares of Incyte Corporation in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. restated a “hold” rating and set a $135.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. Finally, Barclays PLC increased their price objective on shares of Incyte Corporation from $135.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. Eight investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $142.16.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply